SEC Form 4 · accession 0001209191-16-153095
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Narachi
Officer — CEO & President · Director
Period of report
Nov 30, 2016
Accepted (ET)
Dec 2, 2016 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 30, 2016 | A | 802 | $1.67 | A | 6,312 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.